ELRIG Research & Innovation 19th March 2013


Richard Rowling Commercial Director of Reinnervate will present on target-based drug activity and post-translational and transcriptional analysis using ex vivo Alvetex®Scaffold three-dimensional cell culture technology. He will be at the event throughout the day to answer any questions you may have and discuss how Alvetex 3D technology can help you in your work.

For further details about this event please go to http://www.planetreg.com/E118103721130535